Study design and participants
type 2 diabetes
TYPE 2 DIABETES
This study had a multicentre, randomised, double-blind within dose groups (DGs), parallel-group, placebo-controlled design, with six dose-escalation schemes for survodutide (BI 456906, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany; electronic supplementary material [ESM] Fig. Eligible participants were aged 18–75 years, had been diagnosed with type 2 diabetes for ≥6 months, had an HbA